Gerardo Contreras
Instituto de Salud Carlos III
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Gerardo Contreras.
Journal of Acquired Immune Deficiency Syndromes | 2009
María Teresa Cuevas; Mercedes Muñoz-Nieto; Miguel Thomson; Elena Delgado; José Antonio Iribarren; Gustavo Cilla; Aurora Fernández-García; Santamaría Jm; María Jesús Lezaun; Laura Jiménez; Leyre Mónica López-Soria; Mercedes Sota; Gerardo Contreras; Rafael Nájera; Lucía Pérez-Álvarez
Objective:To determine the introduction of HIV-1 genetic forms and to examine transmission clusters and resistance to antiretroviral inhibitors among newly diagnosed patients from the Basque Country, Spain, during 2004-2007. Methods:A total of 261 samples, corresponding to 47.5% heterosexuals, 37.9% men who have sex with men (MSM), and 11.1% intravenous drug users were analyzed in protease and reverse transcriptase to examine phylogenetic relationships and drug resistance-associated mutations. Results:Subtype B was detected in 220 (84.3%) samples and non-B subtype variants in 41 (15.7%) samples. Nearly half (47%) of the sequences grouped in transmission clusters. One of these comprised 14 individuals, 12 of them MSM, with the T215D revertan mutation. In largest transmission clusters, the percentage of MSM was higher than heterosexuals (P < 0.001). Resistance mutations were detected in 29 (11.1%) patients: 20 (7.6%) of them to nucleoside reverse transcriptase inhibitor; 6 (2.3%) to nonnucleoside reverse transcriptase inhibitor (NNRTI); and 1 each to protease inhibitors, protease inhibitor plus NNRTI, and nucleoside reverse transcriptase inhibitor plus NNRTI, respectively. Conclusions:Our findings underscore recommendations for HIV-1 genotyping in newly diagnosed patients not only to provide information on transmitted drug resistance as an issue in public health and as a guide to future therapy but also to document transmission clusters and to increase the necessary preventive measures.
AIDS Research and Human Retroviruses | 2009
Aurora Fernández-García; María Teresa Cuevas; Mercedes Muñoz-Nieto; Antonio Ocampo; Milagros Pinilla; Valentina García; E. Serrano-Bengoechea; María Jesús Lezaun; Elena Delgado; Miguel Thomson; María González-Galeano; Gerardo Contreras; Rafael Nájera; Lucía Pérez-Álvarez
The aim of this study was the development of a panel constituted by well-defined HIV-1 strains of different genetic forms, with a particular focus on isolates from acute and recent infections. Fourteen HIV-1 isolates, including four from acute and five from recent infections, were expanded in peripheral blood mononuclear cells. SI phenotype, coreceptors use, and TCID(50)/ml were determined. V3 net charge was calculated. Near full-length genomes were amplified by RT-nested PCR in four overlapping segments. Phylogenetic analyses were performed with neighbor-joining trees and bootscanning. Analysis of cysteine residues, lengths of variable regions, and potential N-linked glycosylation sites in gp120 and gp41 was performed. Viral stocks were produced. Thirteen strains were NSI/R5 and one SI/R5,X4. TCID(50)/ml ranged between 10(4.6) and 10(6). V3 net charge was <+5 in 12 sequences and +5 in two sequences. Near full-length HIV-1 genomes analysis identified viruses of the following genetic forms: eight subtype B, three subtype C, two CRF02_AG, and one subtype G. Cysteine residues that form the V1,V2,V3, and V4 loops were highly conserved. The number of potential N-linked glycosylation sites in gp120 and gp41 ranged between 24-29 and 4-6, respectively. Seven potential N-linked glycosylation sites in gp120 and three in gp41 were conserved. V1, V2, V4, and V5 variable regions exhibited substantial length variation. In addition, an analysis of transmitted and natural resistance to current antiretroviral drugs in these strains was performed. It is worth mentioning that the 13S mutation in the V3 sequence, associated with resistance to maraviroc, was observed in a subtype B strain that harbored resistance mutations to nucleoside reverse transcriptase inhibitors and to T20. The availability of a panel including strains from acute and recent infections should be a valuable resource for optimizing and standardizing vaccine candidate assessment. Near full-length genome characterization may be necessary for evaluating clade-specific reactivities.
Journal of NeuroVirology | 2003
Cesare Giovanni Fedele; Maria Rosa Ciardi; S. Delia; Gerardo Contreras; José Luis Perez; María de Oña; Elisa Vidal; Antonio Tenorio
Progressive multifocal leukoencephalopathy (PML) is a fatal demyelinating disease of the central nervous system (CNS) caused by the human polyomavirus JC (JCV). JCV has a hypervariable noncoding transcriptional control region (TCR) that spans the origin of replication of the JCV genome through to the first ATG start codon for late gene transcription. The archetype form of TCR is frequently found in the urine and kidneys of healthy and immunocompromised subjects. However the rearranged forms, whose prototype is Mad-1, possibly generated by deletion and duplication of segments of the archetype sequence, are found in the brain and cerebrospinal fluid (CSF) of PML patients. In this study the authors compared JCVTCR detected in paired CSF, plasma, and urine samples of 11 acquired immunodeficiency syndrome (AIDS) patients affected by PML to try to determine where the rearranged JCV TCRs are selected. In one patient, it was also possible to amplify and sequence the TCR in the brain and lymphocytes. Moreover, in 5/11 patients, the CSF, plasma, and urine samples corresponding to 2 months after PML development were available; and in another patient, it was possible to sequence the TCR in plasma and lymphocytes sampled 8 months before the onset of PML. The presence of the same TCR sequences in all the CSF and plasma samples taken from individual patients could strengthen the hypothesis that the blood is a compartment where JCV may replicate and undergo rearrangement of the TCR. This further supports the hypothesis that JCV reaches the brain by a hematogenous route and indicates that the JCV TCR sequences detected in plasma could be used as an early marker of JCV pathogenicity before the clinical appearance of PML in immunocompromised patients.
AIDS Research and Human Retroviruses | 2008
Mercedes Muñoz-Nieto; Lucía Pérez-Álvarez; Miguel Thomson; Valentina García; Antonio Ocampo; Gema Casado; Elena Delgado; Celia Miralles; Elena Vázquez-de Parga; María Sierra; Gerardo Contreras; Rafael Nájera
ABSTRACT The aim of this study was to characterize the HIV-1 intersubtype recombinant forms generated during the follow-up of a dual natural infection with subtypes B and G. Near full-length sequences from plasma and peripheral blood mononuclear cell (PBMC) compartments were analyzed and the biological characteristics of their derived primary isolates studied. Different mutations were detected in V1, V2, and V3 sequences from primary isolates but not in sequences from plasma RNA or PBMC DNA. The HIV-1 near full-length sequence from the first collected plasma was of subtype G and the presence of subpopulations of subtypes B and G was observed with subtype-specific primers for protease and reverse transcriptase segments. Subsequent sequences from plasma, PBMCs, and primary isolates were obtained during a follow-up of 6 years; all of them were BG recombinants and showed identical intersubtype breakpoints between subtypes B and G in pol and nef. The env sequence from all primary isolates harbored a unique insert of subtype B. Specific primers for the V3 loop identified fluctuating subtype B and/or subtype G sequences either from plasma RNA or PBMC DNA.
Journal of Clinical Microbiology | 2005
Yolanda Vega; Lucía Pérez-Álvarez; Elena Delgado; Mercedes Muñoz; Gema Casado; Rocío Carmona; María Sierra; Elena Vázquez-de Parga; Milagros Pinilla; Valentina García; Leandro Medrano; Gerardo Contreras; Miguel Thomson; Rafael Nájera
ABSTRACT The oligonucleotide ligation assay is a genotypic assay for the detection of resistance-associated mutations to reverse transcriptase and protease inhibitors in human immunodeficiency virus type 1 subtype B. This assay has been modified and developed for non-B subtypes and recombinant strains and has been evaluated with sequencing, resulting in a more sensitive assay than sequencing for non-B subtypes.
Archive | 1992
A. Stroobant; M. Denayer; A. M. Worm; M. Stangerup; A. Pönkä; L. Meyer; J. Stratigos; M. Hadjivassiliou Pappa; S. Salmaso; A. Granholt; J. Cardoso; I. Santo; Gerardo Contreras; L. Pérez Álvarez; N. Billo
It is admitted that, although at the present time HIV appears to be largely confined to specific high risk groups, the sexually active population as a whole should be regarded as at risk for HIV. Several high risk groups, especially bisexual males and IV drug users, indeed might act as bridges for the infection into the heterosexual population.
AIDS | 2000
Michael M. Thomson; Maria Luisa Villahermosa; Elena Vázquez-de-parga; María Teresa Cuevas; Elena Delgado; Nuria Manjon; Leandro Medrano; Lucía Pérez-Álvarez; Gerardo Contreras; Manuel Gomez Carrillo; Horacio Salomon; Rafael Nájera
Journal of Clinical Virology | 2005
Rocío Carmona; Lucía Pérez-Álvarez; Mercedes Muñoz; Gema Casado; Elena Delgado; María Sierra; Miguel Thomson; Yolanda Vega; E. Vázquez de Parga; Gerardo Contreras; Leandro Medrano; Rafael Nájera
Infection, Genetics and Evolution | 2005
María Sierra; Michael M. Thomson; Maritza Ríos; Gema Casado; Raúl Ojea-de Castro; Elena Delgado; Gloria Echevarría; Mercedes Muñoz; Javier Colomina; Rocío Carmona; Yolanda Vega; Elena Vázquez-de Parga; Leandro Medrano; Lucía Pérez-Álvarez; Gerardo Contreras; Rafael Nájera
Journal of Medical Virology | 2006
Lucía Pérez-Álvarez; Rocío Carmona; A. Ocampo; A. Asorey; C. Miralles; S. Pérez de Castro; M. Pinilla; Gerardo Contreras; J.A. Taboada; Rafael Nájera